

1 **Early childhood linear growth failure in low- and middle-income countries**

2  
3 Jade Benjamin-Chung,<sup>1\*</sup> Andrew Mertens,<sup>1</sup> John M Colford Jr,<sup>1</sup> Alan E Hubbard,<sup>1</sup> Mark J van der Laan,<sup>1</sup>  
4 Jeremy Coyle<sup>1</sup>, Oleg Sofrygin,<sup>1</sup> Wilson Cai,<sup>1</sup> Anna Nguyen,<sup>1</sup> Nolan N Pokpongkiat,<sup>1</sup> Stephanie Djajadi,<sup>1</sup>  
5 Anmol Seth,<sup>1</sup> Wendy Jilek,<sup>1</sup> Esther O Chung,<sup>1</sup> Sonali Dayal,<sup>1</sup> Nima Hejazi,<sup>1</sup> Ivana Malenica,<sup>1</sup> Haodong Li,<sup>1</sup>  
6 Ryan Hafen,<sup>2</sup> Vishak Subramoney,<sup>3</sup> Jonas Häggström,<sup>4</sup> Thea Norman,<sup>5</sup> Kenneth H. Brown,<sup>6</sup> Parul  
7 Christian,<sup>7</sup> Benjamin F. Arnold,<sup>1,8,9\*</sup> and members of the *ki* Child Growth Consortium‡

8  
9 <sup>1</sup> Division of Epidemiology & Biostatistics, University of California, Berkeley, 2121 Berkeley Way Rm 5302  
10 Berkeley, CA 94720-7360

11 <sup>2</sup> Hafen Consulting, LLC, West Richland WA, 99353

12 <sup>3</sup> Certara Canada, 2000 Peel St, Montreal, Quebec H3A 2W5, Canada

13 <sup>4</sup> MTEK Sciences 802-777 West Broadway, Vancouver, BC, V5Z 1J8, Canada

14 <sup>5</sup> Quantitative Sciences, Bill & Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109

15 <sup>6</sup> Department of Nutrition, University of California, Davis, 3135 Meyer Hall, Davis, CA 95616-5270

16 <sup>7</sup> Maternal, Newborn & Child Health Discovery & Tools, Bill & Melinda Gates Foundation, 500 5th Ave N,  
17 Seattle, WA 98109

18 <sup>8</sup> Francis I. Proctor Foundation, University of California, San Francisco, 95 Kirkham St, San Francisco, CA  
19 94143

20 <sup>9</sup> Department of Ophthalmology, University of California, San Francisco, 10 Koret Way, San Francisco, CA  
21 94143

22

23 \* Corresponding authors:

24

25 Jade Benjamin-Chung, [jadebc@berkeley.edu](mailto:jadebc@berkeley.edu), Division of Epidemiology & Biostatistics, University of  
26 California, Berkeley, 2121 Berkeley Way Rm 5302 Berkeley, CA 94720-7360

27

28 Benjamin F. Arnold, [ben.arnold@ucsf.edu](mailto:ben.arnold@ucsf.edu), Francis I. Proctor Foundation, University of California, San  
29 Francisco, 95 Kirkham St, San Francisco, CA 94143

30

31

32 **Abstract**

33

34 Globally 149 million children under five are estimated to be stunted (length more than 2 standard  
35 deviations below international growth standards). Stunting, a form of linear growth failure, increases  
36 risk of illness, impaired cognitive development, and mortality. Global stunting estimates rely on cross-  
37 sectional surveys, which cannot provide direct information about the timing of onset or persistence of  
38 growth failure— a key consideration for defining critical windows to deliver preventive interventions.  
39 We performed the largest pooled analysis of longitudinal studies in low- and middle-income countries to  
40 date (n=31 cohorts, 62,993 children, ages 0-24 months), allowing us to identify the typical age of linear  
41 growth failure onset and to investigate recurrent faltering in early life. The highest incidence of stunting  
42 onset occurred from birth to age 3 months. From 0 to 15 months, less than 5% of children per month  
43 reversed their stunting status, and among those who did, stunting relapse was common. Early timing  
44 and low reversal rates emphasize the importance of preventive intervention delivery within the prenatal  
45 and early postnatal phases coupled with continued delivery of postnatal interventions through the first  
46 1000 days of life.

47

48

49 ‡ Members of the *ki* Child Growth Consortium

- 50 1. Souheila Abbeddou, Food Safety and Nutrition Unit, Department of Public Health and Primary  
51 Care, Ghent University, Belgium
- 52 2. Linda S. Adair, Department of Nutrition, University of North Carolina at Chapel Hill, USA
- 53 3. Tahmeed Ahmed, International Centre for Diarrhoeal Disease Research, Bangladesh
- 54 4. Asad Ali, Aga Khan University
- 55 5. Hasmat Ali, JiVitA Project, Bangladesh, Johns Hopkins
- 56 6. Per Ashorn, Center for Child Health Research, Tampere University and Tampere University  
57 Hospital, Finland
- 58 7. Rajiv Bahl, World Health Organization, Switzerland
- 59 8. France Bégin, UNICEF, USA
- 60 9. Pascal Obong Bessong, HIV/AIDS & Global Health Research Programme, University of Venda,  
61 South Africa
- 62 10. Maharaj Kishan Bhan, Indian Institute of Technology, New Delhi, India
- 63 11. Nita Bhandari, Centre for Health Research and Development, Society for Applied Studies, New  
64 Delhi, India
- 65 12. Santosh K. Bhargava, Senior Consultant Pediatrics, Sunder Lal Jain Hospital, Ashok Vihar, India
- 66 13. Robert E. Black, Johns Hopkins University
- 67 14. Ladaporn Bodhidatta, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
- 68 15. Delia Carba, USC Office of Population Studies Foundation, Inc., University of San Carlos, Cebu,  
69 Philippines
- 70 16. Ines Gonzales Casanova, Rollins School of Public Health, Emory University, USA
- 71 17. William Checkley, Johns Hopkins University, USA
- 72
- 73 19. Jean E. Crabtree, Leeds Institute for Medical Research, St. James's University Hospital, University  
74 of Leeds, United Kingdom
- 75 20. Kathryn G. Dewey, Institute for Global Nutrition, Department of Nutrition, University of  
76 California, USA
- 77 21. Christopher P. Duggan, Center for Nutrition, Boston Children's Hospital, USA
- 78 22. Caroline H.D. Fall, Professor of International Paediatric Epidemiology, MRC Lifecourse  
79 Epidemiology Unit, University of Southampton, United Kingdom
- 80 23. Abu Syed Golam Faruque, International Centre for Diarrhoeal Disease Research, Bangladesh
- 81 24. Wafaie W. Fawzi, Department of Global Health and Population, Harvard TH Chan School of  
82 Public Health, USA
- 83 25. José Quirino da Silva Filho, Federal University of Ceará, Brazil
- 84 26. Robert H. Gilman, Johns Hopkins University Bloomberg School of Public Health, USA
- 85 27. Richard Guerrant, University of Virginia, USA
- 86 28. Rashidul Haque, International Centre for Diarrhoeal Disease Research, Bangladesh
- 87 29. Sonja Y. Hess, Dept of Nutrition and Institute for Global Nutrition, University of California Davis,  
88 USA
- 89 30. Eric R. Houpt, University of Virginia, USA
- 90 31. Jean H. Humphrey, Johns Hopkins Bloomberg School of Public Health, USA
- 91 32. Najeeha Talat Iqbal, Department of Pediatrics and Child Health, Aga Khan University, Pakistan
- 92 33. Elizabeth Yakes Jimenez, Departments of Pediatrics and Internal Medicine, University of New  
93 Mexico Health Sciences Center, USA
- 94 34. Jacob John, Christian Medical College, Vellore, Tamil Nadu, India
- 95 35. Sushil Matthew John, Low Cost Effective Care Unit, Christian Medical College, Vellore, Tamil  
96 Nadu, India

- 97 36. Gagandeep Kang, Translational Health Science and Technology Institute, Faridabad, Haryana,  
98 India
- 99 37. Margaret Kosek, University of Virginia, USA
- 100 38. Michael S. Kramer, McGill University and McGill University Health Centre, Canada
- 101 39. Alain Labrique, Center of Human Nutrition, Department of International Health, Johns  
102 Hopkins Bloomberg School of Public Health, USA
- 103 40. Nanette R. Lee, USC-Office of Population Studies Foundation Inc., University of San Carlos, Cebu,  
104 Philippines
- 105 41. Aldo Ângelo Moreira Lima, Federal University of Ceará, Brazil
- 106 42. Mustafa Mahfuz, International Centre for Diarrhoeal Disease Research, Bangladesh
- 107 43. Tjale Cloupas Mahopo, Department of Nutrition, School of Health Sciences, University of Venda,  
108 South Africa
- 109 44. Kenneth Maleta, Department of Public Health, School of Public Health and Family Medicine,  
110 College of Medicine, University of Malawi, Malawi
- 111 45. Dharma S. Manandhar, Mother and Infant Research Activities, Nepal
- 112 46. Karim P. Manji, Department of Pediatrics and Child Health, Muhimbili University School of  
113 Health and Allied Sciences, Dar es Salaam, Tanzania
- 114 47. Reynaldo Martorell, Rollins School of Public Health, Emory University, USA
- 115 48. Sarmila Mazumder, Centre for Health Research and Development, Society for Applied Studies,  
116 New Delhi, India
- 117 49. Estomih Mduma, Haydom Lutheran Hospital, Haydom, Tanzania
- 118 50. Venkata Raghava Mohan, Professor, Community Medicine, Christian Medical College, Vellore  
119 Tamil Nadu, India
- 120 51. Sophie E. Moore, Department of Women and Children's Health, Kings College London, London,  
121 UK & MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, United Kingdom
- 122 52. Ishita Mostafa, International Centre for Diarrhoeal Disease Research, Bangladesh
- 123 53. Robert Ntozini, Zvitambo Institute for Maternal and Child Health Research, Zimbabwe
- 124 54. Mzwakhe Emanuel Nyathi, Department of Animal Sciences, School of Agriculture, University of  
125 Venda, South Africa
- 126 55. Maribel Paredes Olortegui, AB PRISMA, Peru
- 127 56. William A. Petri, University of Virginia, USA
- 128 57. Prasanna Samuel Premkumar, Christian Medical College, Vellore, Tamil Nadu, India
- 129 58. Andrew M. Prentice, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine,  
130 Banjul, The Gambia
- 131 59. Najeeb Rahman, Aga Khan University, Pakistan
- 132 60. Harshpal Singh Sachdev, Senior Consultant Pediatrics and Clinical Epidemiology, Sitaram Bhartia  
133 Institute of Science and Research, B-16 Qutab Institutional Area, New Delhi, India
- 134 61. Kamran Sadiq, Aga Khan University, Pakistan
- 135 62. Rajiv Sarkar, Christian Medical College, Vellore, Tamil Nadu, India
- 136 63. Naomi M. Saville, Institute for Global Health, University College London, United Kingdom
- 137 64. Saijuddin Shaikh, Johns Hopkins and JiVitA Project, Bangladesh
- 138 65. Bhim P. Shrestha, Health Research and Development Forum, Kathmandu, Nepal
- 139 66. Sanjaya Kumar Shrestha, MD, Walter Reed/AFRIMS Research Unit, Kathmandu, Nepal, Centre  
140 for International Health, University of Bergen, Norway
- 141 67. Alberto Melo Soares, Federal University of Ceará, Brazil
- 142 68. Bakary Sonko, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, Banjul,  
143 The Gambia

- 144 69. Aryeh D. Stein, Hubert Department of Global Health, Rollins School of Public Health, Emory  
145 University, USA  
146 70. Erling Svensen, Haukeland University Hospital, Norway  
147 71. Sana Syed, Department of Pediatrics, Division of Gastroenterology, Hepatology & Nutrition  
148 University of Virginia School of Medicine, and Aga Khan University, Pakistan  
149 72. Fayaz Umrani, Aga Khan University, Pakistan  
150 73. Honorine D. Ward, Tufts Medical Center, Tufts University School of Medicine, USA  
151 74. Keith P. West Jr., Center for Human Nutrition, Department of International Health, Johns  
152 Hopkins Bloomberg School of Public Health, USA  
153 75. Lee Shu Fune Wu, Center for Human Nutrition, Department of International Health, Johns  
154 Hopkins Bloomberg School of Public Health, USA  
155 76. Seungmi Yang, McGill University, Canada  
156 77. Pablo Penataro Yori, University of Virginia, USA  
157

158 **Introduction**

159

160 There have been marked reductions in child mortality in the past decade,<sup>1</sup> in part due to the  
161 emphasis on child survival in the Millennium Development Goals. Yet children born in low- and middle  
162 income countries (LMICs) still face enormous challenges to their ability to thrive, including poverty, poor  
163 nutrition, poor water and sanitation, poor access to health care and limited stimulation in the home  
164 environment.<sup>2</sup> A commonly used, readily measurable indicator of children’s overall health and  
165 development is their linear growth as measured by a child’s length (height or stature).<sup>3</sup> Extensive  
166 evidence supports its use as a surrogate for more difficult-to-measure physiological and cognitive  
167 deficits that accrue during early life.<sup>4,5</sup> Children in optimal environments have the same growth  
168 potential, regardless of their geographic location<sup>6</sup>, and thus the World Health Organization (WHO) has  
169 developed international standards for child growth.<sup>7</sup> A child is “stunted” if his or her length is more than  
170 2 standard deviations below the median of the growth standard for age and sex. In 2018, 149 million  
171 children under 5 years (22% globally) were stunted, with the largest burden in South Asia and Africa.<sup>8,9</sup>  
172 Early life stunting is associated with increased risk of mortality,<sup>10</sup> diarrhea, pneumonia, and measles in  
173 childhood<sup>11,12</sup> and impaired cognition and productivity in adulthood.<sup>3,13,14</sup> Global income would increase  
174 by an estimated \$176.8 billion per year if linear growth failure could be eliminated.<sup>15</sup> The WHO 2025  
175 Global Nutrition Targets<sup>16</sup> and Sustainable Development Goal 2 propose to reduce stunting prevalence  
176 from 2012 levels by 40% by 2025,<sup>17</sup> reflecting renewed attention to child growth as a key determinant of  
177 overall health and human capital.<sup>18</sup>

178

179 The age of stunting onset has direct implications for the timing and nature of preventive public  
180 health interventions. In low-resource settings, most linear growth failure occurs in the first 2 years of  
181 life, and 70% of absolute length deficits by age 5 years occur before age 2 years.<sup>3</sup> Beyond this age, catch  
182 up growth is rare in the absence of radical improvements to a child’s nutrition, health, and  
183 environment.<sup>19–23</sup> Intrauterine growth restriction and preterm birth are strongly associated with the risk  
184 of stunting at 24 months of age,<sup>24</sup> and the first 1000 days of life is considered the critical window in  
185 which to intervene to prevent stunting.<sup>6,25</sup>

186

187 Granular information about age of linear growth failure onset and its persistence in early life will  
188 best inform when and how to intervene with preventive measures. Yet, most studies of the global  
189 epidemiology and burden of stunting have pooled nationally representative, cross-sectional surveys –  
190 predominantly national Demographic Health Surveys (DHS) – to estimate age-specific stunting  
191 prevalence.<sup>23,26–28</sup> Cross-sectional studies cannot identify the timing of linear growth failure onset  
192 because they measure prevalence, which cannot distinguish between persistent and new cases of  
193 growth failure. Few studies have reported stunting incidence,<sup>29,30</sup> and even fewer have estimated age-  
194 specific incidence within the first two years of life to inform the timing of intervention delivery.<sup>31–33</sup> We  
195 conducted an in-depth study of linear growth failure incidence in a pooled analysis of 31 longitudinal  
196 cohorts with multiple, frequent measurements in LMICs. The analysis provides new insights into the  
197 timing of onset and duration of linear growth failure, with important implications for interventions. We  
198 found that linear growth failure occurs very early in the prenatal and postnatal phase – before the age  
199 when most postnatal linear growth interventions begin (age 6 months). Our findings confirm the  
200 importance of the first 1,000 days as a critical window to intervene to prevent linear growth failure, but  
201 motivate a renewed focus on interventions delivered in the prenatal and early postnatal periods.

202

203

204

205

## 206 Pooled longitudinal analyses

207  
208 Here, we report a pooled analysis of 31 longitudinal cohorts from 15 LMICs in South Asia, Sub-  
209 Saharan Africa, and Latin America followed between 1969 and 2014. Our objective was to estimate age-  
210 specific incidence and prevalence of stunting as well as linear growth velocity from 0 to 24 months. A  
211 companion article in this issue reports results for child wasting (weight-for-length Z-score < 2 standard  
212 deviations below the reference median).<sup>34</sup> These data were amassed as part of the Knowledge  
213 Integration (*ki*) initiative of the Bill & Melinda Gates Foundation, which aggregated observations on  
214 millions of participants from a global collection of studies on child birth, growth and development.<sup>35</sup> We  
215 selected longitudinal cohorts from the database that met five inclusion criteria: 1) conducted in LMICs;  
216 2) enrolled children between birth and age 24 months and measured their length and weight repeatedly  
217 over time; 3) did not restrict enrollment to acutely ill children; 4) enrolled at least 200 children; and 5)  
218 collected anthropometry measurements at least every 3 months (Extended Data Fig 1). These inclusion  
219 criteria ensured we could rigorously evaluate the timing and onset of stunting among children who were  
220 broadly representative of general populations in LMICs. For included randomized trials, if trials found  
221 effects on growth within the intervention arms, the analysis was limited to the control arm. Thirty-one  
222 cohorts met inclusion criteria, including 62,993 children and 464,345 total measurements (Fig 1). Most  
223 cohorts were enrolled within the past 10 years (Extended Data Table 1). Cohorts were distributed  
224 throughout South Asia, Eastern, Southern, and Western Africa, and Latin America, and a single cohort  
225 from Eastern Europe (Belarus) met inclusion criteria. Among included cohorts, 18 measured children at  
226 least monthly, and 13 measured children every 3 months (quarterly). Cohort sample sizes varied from  
227 215 to 14,074 children. Despite broad global reach, geographic distribution was not representative of  
228 entire regions or continents (Extended Data Fig 2).

229  
230 We calculated length-for-age Z-scores (LAZ) using WHO 2006 growth standards.<sup>7</sup> We dropped 969  
231 out of 465,314 measurements (0.2%) because LAZ was unrealistic ( $> 6$  or  $< -6$  Z), and we defined  
232 stunting as  $LAZ < -2$  and severe stunting as  $LAZ < -3$ .<sup>7</sup> Unless otherwise indicated, estimates that pool  
233 across cohorts used random effects models fit with restricted maximum likelihood estimation.<sup>36,37</sup>  
234 Within each cohort the monthly mean LAZ ranged from  $-3.18$  to  $+1.31$ , and the monthly proportion  
235 stunted ranged from 0.3% to 86.1% (Fig 1). We compared LAZ from included cohorts with those of  
236 contemporary population-based, cross-sectional DHS data for children 0-24 months of age in the same  
237 countries and regions to assess their representativeness. Cohorts had similar Z-score distributions as  
238 their target populations (Fig 2a). Mean LAZ by age was approximately 0.25-0.75 standard deviations  
239 lower in included *ki* cohorts than in DHS surveys in the same countries in South Asia and Africa, and  
240 mean LAZ by age was slightly higher in Latin American cohorts (Fig 2b). Analyses therefore include a  
241 large set of cohorts from populations with high burdens of growth failure but are not representative of  
242 entire world regions. The width of the LAZ distribution was unimodal and similar to that of the WHO  
243 child growth standard's LAZ distribution, consistent with the assertion that linear growth failure is a  
244 "whole population" condition.<sup>27</sup>

245  
246 Age-specific patterns of mean LAZ and stunting prevalence were consistent with prior analyses of  
247 cross-sectional survey data.<sup>26,27</sup> Most children were born with linear growth deficits: mean LAZ at birth  
248 was  $-0.75$  (Fig 2a). LAZ declined steadily from birth, and by 24 months mean LAZ was  $-1.82$ . South Asia  
249 had lower LAZ than other regions: mean LAZ at birth was  $-1.04$  and the mean at 24 months was  $-2.01$ .  
250 Yet, the decline in mean LAZ was the largest in Africa, where the mean LAZ at birth was  $-0.56$  and the  
251 mean at 24 months was  $-1.87$ . Linear growth failure was evident across percentiles of the LAZ  
252 distribution; in South Asia, the 95<sup>th</sup> percentile of children's LAZ scores dropped below 0 by age 14  
253 months (Extended Data Fig 3). At birth, the overall prevalence of stunting ( $LAZ < -2$ ) was 12%; prevalence

254 increased steadily to 43% at 18 months and remained stable thereafter (Fig 3a). In African cohorts,  
255 stunting prevalence increased steadily each month from 10% at birth to 44% at 24 months. In South  
256 Asia, 18% of children were born stunted, and stunting prevalence increased steadily to 53% at 18  
257 months and then decreased to 48% at 24 months. At most ages, stunting prevalence and incidence were  
258 lower in Latin America; wider confidence intervals for this region reflect greater variation between  
259 cohorts because stunting was more common in Guatemala than in other countries ([https://child-  
260 growth.github.io/stunting/cohort.html](https://child-growth.github.io/stunting/cohort.html)).

261

### 262 **Onset of stunting in early life**

263

264 To measure the timing of stunting onset, we classified a child as a new incident case in three-month  
265 age periods if their LAZ dropped below  $-2$  for the first time in that age period. Across cohorts, 12% of  
266 children were stunted at birth, and 17% experienced incident stunting onset between birth and 3  
267 months (Fig 3b); children stunted between birth and 3 months accounted for 40% of all children who  
268 experienced stunting by age 24 months (65% of children). Trends were similar for severe stunting  
269 (<https://child-growth.github.io/stunting/severe-stunting.html>).

270

271 In an exploratory analysis, we stratified age-specific mean LAZ by age of stunting onset among  
272 children in monthly measured cohorts and observed three distinct subgroups whose mean LAZ followed  
273 statistically different trajectories (Fig 3c). 26% of all children were born with linear growth deficits (mean  
274 LAZ  $< -1$ ), and their mean LAZ stabilized around  $-2$  from age 1 month onward, with differences at birth  
275 in this group converging through likely regression to the mean. 11% of children were born with small  
276 linear growth deficits on average (mean  $0 < \text{LAZ} < -1$  at birth) and reached a mean of  $-2$  at subsequent  
277 ages. The remaining 62% of children maintained mean LAZ  $> -2$  at all ages, but mean LAZ declined  
278 steadily from birth to 15 months. Overall trends in mean LAZ were consistent with our age-specific  
279 incidence and prevalence estimates (Fig 3a-b). Children born with linear growth deficits may benefit  
280 more from prenatal interventions, while those whose mean LAZ declined later may benefit from both  
281 prenatal and postnatal interventions. A companion article reports characteristics that increase risk of  
282 earlier versus later growth failure.<sup>35</sup>

283

### 284 **Stunting reversal and relapse**

285

286 Stunting prevalence and incidence estimates classify linear growth measures into binary categories,  
287 which could mask the dynamics of linear growth failure onset and reversal across the continuous range  
288 of LAZ.<sup>5,38,39</sup> We hypothesized that lower than average linear growth (LAZ  $< 0$ ) would persist among  
289 children who experienced stunting reversal (i.e., LAZ increased from below  $-2$  to above  $-2$ ). In addition,  
290 we hypothesized that children who experienced stunting reversal would experience stunting relapse at  
291 later ages. To test these hypotheses, we classified a child's change in stunting status from birth to 15  
292 months among monthly-measured cohorts (measurement frequency beyond 15 months was less  
293 consistent) (Fig 4a). Initial onset of stunting occurred before age 6 months for a majority of children. The  
294 proportion of children who experienced stunting reversal was less than 5% per month from ages 2 to 7  
295 months and was lower at subsequent ages.

296

297 Among children who experienced stunting reversal, we summarized the LAZ distribution at older  
298 ages. We then estimated the mean difference in LAZ measured at older ages compared to when stunting  
299 was reversed. At the time of stunting reversal, the mode of the distribution of LAZ scores was close to  
300 the  $-2$  cutoff (Fig 4b). As children aged, LAZ distributions gradually shifted downwards, illustrating that  
301 linear growth deficits continued to accumulate. The mean LAZ decreased by up to 0.71 SDs from 3 to 12

302 months after stunting reversal, and the older a child was at the time of reversal, the larger the decline in  
303 subsequent LAZ (Fig 4c). Overall, improvements in LAZ among children whose stunting status reversed  
304 were neither sustained nor large enough to erase linear growth deficits, indicating that stunting reversal  
305 did not resemble a biological recovery process for many children.

306

### 307 **Growth velocity by age and sex**

308

309 Age-specific growth velocity provides a complementary view of child growth failure only possible in  
310 longitudinal cohorts. We defined linear growth velocity as the change in length between two time points  
311 divided by the number of months between the time points (cm/month). We also estimated within-child  
312 rates of change in LAZ per month. The change in LAZ per month measures the extent to which a child's  
313 length relative to WHO standards for his or her age and sex changed over time. From 0-3 months, length  
314 velocity was in between the 15<sup>th</sup> and 25<sup>th</sup> percentile of the WHO standard for girls and was close to the  
315 15<sup>th</sup> percentile for boys; velocity for both sexes then improved relative to WHO standards as children  
316 aged (Fig 5a). Larger deficits at the youngest ages were consistent with highest incidence of stunting  
317 from birth to age 3 months (Fig 3b). LAZ velocity was similar for male and female children (Fig 5b).  
318 Patterns were similar across geographic regions (Extended Data Fig 4a, 4b).

319

320 The accumulation of growth velocity deficits was reflected in lower mean LAZ for boys than girls  
321 across all ages (Fig 5c). Overall patterns were similar across geographic regions (Extended Data Fig 4c).  
322 Worse growth among boys is consistent with higher infant mortality rates among boys found around the  
323 world, suggesting that males may be more vulnerable than females in early life,<sup>40-46</sup> or that evolutionary  
324 selection favors females in resource-poor environments.<sup>47</sup>

325

### 326 **Discussion**

327

328 Estimates of the global burden of stunting and timing of linear growth failure have relied largely on  
329 cross-sectional surveys that have indicated the need for interventions targeted to children younger than  
330 24 months.<sup>6,25</sup> This large-scale, longitudinal analysis of 31 prospective cohorts from LMICs allowed us to  
331 provide new insights into the timing, persistence, and recurrence of linear growth failure within the first  
332 2 years of life. Prevalence estimates matched general patterns reported in cross-sectional studies,  
333 gradually increasing with age.<sup>23,26-28</sup> Yet, incidence estimates from longitudinal analyses revealed a  
334 starkly different age-specific pattern and showed that stunting incidence was highest from birth to 3  
335 months and declined thereafter (Fig 3a-b). The vast majority of children who experienced stunting  
336 reversal (i.e., crossed above the  $\leq -2$  LAZ cut-off) continued to experience linear growth deficits, and  
337 over 20% were stunted again at later measurements (Fig 4).

338

339 Pre-pregnancy and prenatal risk factors for postnatal linear growth failure include young maternal  
340 age,<sup>48</sup> maternal infection,<sup>49</sup> and maternal undernutrition, including low pre-pregnancy body mass index,  
341 short stature, and inadequate gestational weight gain.<sup>50</sup> Rigorous evaluations of interventions to address  
342 these predictors have been limited to date. Interventions to improve maternal nutrition<sup>51</sup> and reduce  
343 adolescent pregnancies in LMICs by delaying the age of marriage and first pregnancy<sup>52</sup> may reduce the  
344 risk of linear growth failure. In addition, interventions to reduce prenatal infections associated with  
345 growth failure, such as intermittent preventive treatment for malaria, may also increase fetal linear  
346 growth in regions where such infections co-occur with linear growth failure.<sup>53</sup>

347

348 In the early postnatal phase (age 0-6 months), when growth velocity and stunting incidence were  
349 highest, the World Health Organization recommends exclusive breastfeeding to prevent infant infection

350 and to support child growth.<sup>54</sup> Exclusive breastfeeding significantly reduces the risk of mortality and  
351 morbidity, but exclusive breastfeeding promotion has not been found to reduce the risk of infant  
352 stunting.<sup>11,55–58</sup> The extent to which exclusive breastfeeding impacts linear growth may depend on  
353 maternal breast milk composition and microbiota, both of which may be impacted by maternal  
354 undernutrition.<sup>59–61</sup> In the complementary feeding phase (age 6-24 months), interventions to reduce  
355 growth failure include energy, protein, and micronutrient supplementation of children; deworming;  
356 water and sanitation improvements; vaccination; and maternal education. However, meta-analyses  
357 evaluating the effectiveness of interventions during the complementary feeding phase on stunting  
358 prevalence and mean LAZ have reported modest impacts of lipid-based nutrient supplements,<sup>62</sup> modest  
359 or no impact of micronutrient supplementation,<sup>63</sup> and no impact of water and sanitation improvements,  
360 deworming, or maternal education.<sup>63</sup> The dearth of postnatal interventions that can effectively improve  
361 child linear growth motivates renewed efforts to identify alternative, possibly multisectoral  
362 interventions, and in parallel improve intervention targeting and implementation.<sup>64,65</sup>

363  
364 There were several limitations to the analyses. First, length estimates may be subject to  
365 measurement error; stunting reversal and relapse analyses that rely on thresholds are more sensitive to  
366 such errors. However, detailed assessments of measurement quality indicated that measurement  
367 quality was high across cohorts (<https://child-growth.github.io/stunting/QA.html>). Second, estimates of  
368 LAZ at birth using the WHO Child Growth Standards overestimate stunting among children who are born  
369 preterm.<sup>66</sup> Accurate estimates of gestational age were not available in included cohorts; seven cohorts  
370 measured gestational age by recall of last menstrual period or newborn examination, and one cohort  
371 measured gestational age by ultrasound. In a sensitivity analysis adjusting for gestational age pooling  
372 across cohorts that measured it, stunting prevalence at birth was 1% lower (Extended Data Fig 5). Third,  
373 included cohorts were not inclusive of all countries in the regions presented here, and linear growth  
374 failure was more common in included African and South Asian cohorts than in corresponding  
375 contemporary representative surveys. However, the consistency between linear growth patterns in this  
376 and nationally representative surveys (Fig 2) suggests that overall our results have good external  
377 validity. Finally, the included cohorts measured child length every 1-3 months, and the exact ages of  
378 measurement varied, so the number of children and cohorts contributing to estimates differs between  
379 analysis strata. However, when we repeated analyses in cohorts with monthly measurements from birth  
380 to 24 months (n=18 cohorts in 10 countries, 10,830 children), results were similar ([https://child-  
381 growth.github.io/stunting/monthly.html](https://child-growth.github.io/stunting/monthly.html)).

## 382 383 Conclusion

384 The WHO Global Nutrition Targets and Sustainable Development Goals set ambitious targets to  
385 improve child linear growth by 2025. Our findings of early linear growth failure onset and infrequent  
386 reversal for a majority of children who faltered support interventions delivered from conception to the  
387 early postnatal phase along with continued delivery of postnatal interventions to prevent linear growth  
388 failure among children in LMICs.

389

390 **References**

- 391 1. UNICEF. Levels and Trends in Child Mortality Report 2018. *UNICEF*  
392 [https://www.unicef.org/publications/index\\_103264.html](https://www.unicef.org/publications/index_103264.html) (2018).
- 393 2. Bhutta, Z. A. & Black, R. E. Current and Future Challenges for Children Across the World. *JAMA*  
394 (2019) doi:10.1001/jama.2019.1840.
- 395 3. de Onis, M. & Branca, F. Childhood stunting: a global perspective. *Matern. Child. Nutr.* **12**, 12–26  
396 (2016).
- 397 4. Grantham-McGregor, S. *et al.* Developmental potential in the first 5 years for children in developing  
398 countries. *Lancet* **369**, 60–70 (2007).
- 399 5. Leroy, J. L. & Frongillo, E. A. Perspective: What Does Stunting Really Mean? A Critical Review of the  
400 Evidence. *Adv. Nutr.* doi:10.1093/advances/nmy101.
- 401 6. Martorell, R. Improved nutrition in the first 1000 days and adult human capital and health. *Am. J.*  
402 *Hum. Biol.* **29**, e22952 (2017).
- 403 7. WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-  
404 age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods  
405 and development. *Geneva World Health Organ.* 312 pages (2006).
- 406 8. *WHO | Joint child malnutrition estimates - Levels and trends (2019 edition)*.  
407 <http://www.who.int/nutgrowthdb/estimates2018/en/> (2019).
- 408 9. Kinyoki, D. K. *et al.* Mapping child growth failure across low- and middle-income countries. *Nature*  
409 **577**, 231–234 (2020).
- 410 10. McDonald, C. M. *et al.* The effect of multiple anthropometric deficits on child mortality: meta-  
411 analysis of individual data in 10 prospective studies from developing countries. *Am. J. Clin. Nutr.* **97**,  
412 896–901 (2013).
- 413 11. Black, R. E. *et al.* Maternal and child undernutrition and overweight in low-income and middle-  
414 income countries. *The Lancet* **382**, 427–451 (2013).

- 415 12. Olofin, I. *et al.* Associations of Suboptimal Growth with All-Cause and Cause-Specific Mortality in  
416 Children under Five Years: A Pooled Analysis of Ten Prospective Studies. *PLoS ONE* **8**, (2013).
- 417 13. Prendergast, A. J. & Humphrey, J. H. The stunting syndrome in developing countries. *Paediatr. Int.*  
418 *Child Health* **34**, 250–265 (2014).
- 419 14. Adair, L. S. *et al.* Associations of linear growth and relative weight gain during early life with adult  
420 health and human capital in countries of low and middle income: findings from five birth cohort  
421 studies. *Lancet* **382**, 525–534 (2013).
- 422 15. Fink, G. *et al.* Schooling and wage income losses due to early-childhood growth faltering in  
423 developing countries: national, regional, and global estimates. *Am. J. Clin. Nutr.* **104**, 104–112  
424 (2016).
- 425 16. World Health Organization. Global Targets 2025. *WHO* [http://www.who.int/nutrition/global-target-](http://www.who.int/nutrition/global-target-2025/en/)  
426 [2025/en/](http://www.who.int/nutrition/global-target-2025/en/).
- 427 17. United Nations. Goal 2. Sustainable Development Knowledge Platform.  
428 <https://sustainabledevelopment.un.org/sdg2>.
- 429 18. Victora, C. G. *et al.* Maternal and child undernutrition: consequences for adult health and human  
430 capital. *Lancet* **371**, 340–357 (2008).
- 431 19. Dewey, K. G. & Begum, K. Long-term consequences of stunting in early life. *Matern. Child. Nutr.* **7**,  
432 5–18 (2011).
- 433 20. Golden, M. H. Is complete catch-up possible for stunted malnourished children? *Eur. J. Clin. Nutr.* **48**  
434 **Suppl 1**, S58-70; discussion S71 (1994).
- 435 21. Boersma, B. & Wit, J. M. Catch-up Growth. *Endocr. Rev.* **18**, 646–661 (1997).
- 436 22. Prentice, A. M. *et al.* Critical windows for nutritional interventions against stunting<sup>123</sup>. *Am. J. Clin.*  
437 *Nutr.* **97**, 911–918 (2013).


- 438 23. Leroy, J. L., Ruel, M., Habicht, J.-P. & Frongillo, E. A. Using height-for-age differences (HAD) instead  
439 of height-for-age z-scores (HAZ) for the meaningful measurement of population-level catch-up in  
440 linear growth in children less than 5 years of age. *BMC Pediatr.* **15**, 145 (2015).
- 441 24. Christian, P. *et al.* Risk of childhood undernutrition related to small-for-gestational age and preterm  
442 birth in low- and middle-income countries. *Int J Epidemiol* **42**, 1340–1355 (2013).
- 443 25. Dewey, K. G. Reducing stunting by improving maternal, infant and young child nutrition in regions  
444 such as South Asia: evidence, challenges and opportunities. *Matern. Child. Nutr.* **12**, 27–38 (2016).
- 445 26. Victora, C. G., Onis, M. de, Hallal, P. C., Blössner, M. & Shrimpton, R. Worldwide Timing of Growth  
446 Faltering: Revisiting Implications for Interventions. *Pediatrics* **125**, e473–e480 (2010).
- 447 27. Roth, D. E. *et al.* Early childhood linear growth faltering in low-income and middle-income countries  
448 as a whole-population condition: analysis of 179 Demographic and Health Surveys from 64 countries  
449 (1993–2015). *Lancet Glob. Health* **5**, e1249–e1257 (2017).
- 450 28. Leroy, J. L., Ruel, M., Habicht, J.-P. & Frongillo, E. A. Linear growth deficit continues to accumulate  
451 beyond the first 1000 days in low- and middle-income countries: global evidence from 51 national  
452 surveys. *J. Nutr.* **144**, 1460–1466 (2014).
- 453 29. Kumar, R., Deshmukh, P. R. & Garg, B. S. Incidence and Correlates of “Growth Faltering” Among 0–6  
454 y Children: A Panel Study from Rural Wardha. *Indian J. Pediatr.* **79**, 333–341 (2012).
- 455 30. Lundeen, E. A. *et al.* Growth faltering and recovery in children aged 1–8 years in four low- and  
456 middle-income countries: Young Lives. *Public Health Nutr.* **17**, 2131–2137 (2014).
- 457 31. Mangani, C. *et al.* Effect of complementary feeding with lipid-based nutrient supplements and corn–  
458 soy blend on the incidence of stunting and linear growth among 6- to 18-month-old infants and  
459 children in rural Malawi. *Matern. Child. Nutr.* **11**, 132–143 (2015).
- 460 32. Maleta, K., Virtanen, S. M., Espo, M., Kulmala, T. & Ashorn, P. Childhood malnutrition and its  
461 predictors in rural Malawi. *Paediatr. Perinat. Epidemiol.* **17**, 384–390 (2003).

- 462 33. Mongkolchaty, A., Thinkhamrop, B., Mo-Suwan, L., Chittchang, U. & Choprapawon, C. Prevalence  
463 and incidence of child stunting from birth to two years of life in Thai children: based on the  
464 Prospective Cohort Study of Thai Children (PCTC). *J. Med. Assoc. Thai. Chotmaiher Thangphaet* **93**,  
465 1368–1378 (2010).
- 466 34. Mertens, A. *et al.* (submitted). Child wasting and concurrent stunting in low- and middle-income  
467 countries. (2020).
- 468 35. Peppard, T. *et al.* (submitted). Combined longitudinal growth cohorts from infants born in South  
469 Asia, Sub-Saharan Africa and Latin America. (2020).
- 470 36. Viechtbauer, W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects  
471 Model. *J. Educ. Behav. Stat.* **30**, 261–293 (2005).
- 472 37. Raudenbush, S. W. Analyzing Effect Sizes: Random-Effects Models. in *The Handbook of Research*  
473 *Synthesis and Meta-Analysis* 295–315 (Russell Sage Foundation, 2009).
- 474 38. Frongillo, E. A., Leroy, J. L. & Lapping, K. Appropriate Use of Linear Growth Measures to Assess  
475 Impact of Interventions on Child Development and Catch-Up Growth. *Adv. Nutr.*  
476 doi:10.1093/advances/nmy093.
- 477 39. Perumal, N., Bassani, D. G. & Roth, D. E. Use and Misuse of Stunting as a Measure of Child Health. *J.*  
478 *Nutr.* **148**, 311–315 (2018).
- 479 40. Leach, A. *et al.* Neonatal mortality in a rural area of The Gambia. *Ann. Trop. Paediatr.* **19**, 33–43  
480 (1999).
- 481 41. Koenig, M. A. & D’Souza, S. Sex differences in childhood mortality in rural Bangladesh. *Soc. Sci. Med.*  
482 **22**, 15–22 (1986).
- 483 42. Wells, J. C. K. Natural Selection and Sex Differences in Morbidity and Mortality in Early Life. *J. Theor.*  
484 *Biol.* **202**, 65–76 (2000).
- 485 43. Ingemarsson, I. Gender aspects of preterm birth. *BJOG Int. J. Obstet. Gynaecol.* **110**, 34–38 (2003).


- 486 44. Sawyer, C. C. Child Mortality Estimation: Estimating Sex Differences in Childhood Mortality since the  
487 1970s. *PLOS Med.* **9**, e1001287 (2012).
- 488 45. Lawn, J., Cousens, S. & Zupan, J. 4 million neonatal deaths: When? Where? Why? *The Lancet* **365**,  
489 891–900 (2005).
- 490 46. Hesketh, T. & Xing, Z. W. Abnormal sex ratios in human populations: Causes and consequences.  
491 *Proc. Natl. Acad. Sci. U. S. A.* **103**, 13271–13275 (2006).
- 492 47. Trivers, R. L. & Willard, D. E. Natural Selection of Parental Ability to Vary the Sex Ratio of Offspring.  
493 *Science* **179**, 90–92 (1973).
- 494 48. Fall, C. H. D. *et al.* Association between maternal age at childbirth and child and adult outcomes in  
495 the offspring: a prospective study in five low-income and middle-income countries (COHORTS  
496 collaboration). *Lancet Glob. Health* **3**, e366–e377 (2015).
- 497 49. Ashorn, P. *et al.* Co-causation of reduced newborn size by maternal undernutrition, infections, and  
498 inflammation. *Matern. Child. Nutr.* **14**, e12585 (2018).
- 499 50. Black, R. E. *et al.* Maternal and child undernutrition: global and regional exposures and health  
500 consequences. *Lancet* **371**, 243–260 (2008).
- 501 51. Das, J. K. *et al.* Lipid-based nutrient supplements for maternal, birth, and infant developmental  
502 outcomes. *Cochrane Database Syst. Rev.* **8**, CD012610 (2018).
- 503 52. Svanemyr, J., Chandra-Mouli, V., Raj, A., Travers, E. & Sundaram, L. Research priorities on ending  
504 child marriage and supporting married girls. *Reprod. Health* **12**, 80 (2015).
- 505 53. Luntamo, M., Kulmala, T., Cheung, Y. B., Maleta, K. & Ashorn, P. The effect of antenatal monthly  
506 sulphadoxine–pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering  
507 in Malawi: a randomised controlled trial. *Trop. Med. Int. Health* **18**, 386–397 (2013).
- 508 54. WHO & UNICEF. *Capture the moment - Early initiation of breastfeeding: the best start for every*  
509 *newborn.* (2018).

- 510 55. Victora, C. G. *et al.* Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong  
511 effect. *The Lancet* **387**, 475–490 (2016).
- 512 56. Bhutta, Z. A. *et al.* What works? Interventions for maternal and child undernutrition and survival.  
513 *The Lancet* **371**, 417–440 (2008).
- 514 57. Giugliani, E. R. J., Horta, B. L., Mola, C. L. de, Lisboa, B. O. & Victora, C. G. Effect of breastfeeding  
515 promotion interventions on child growth: a systematic review and meta-analysis. *Acta Paediatr.*  
516 **104**, 20–29 (2015).
- 517 58. Eriksen, K. G. *et al.* Following the World Health Organization’s Recommendation of Exclusive  
518 Breastfeeding to 6 Months of Age Does Not Impact the Growth of Rural Gambian Infants. *J. Nutr.*  
519 **147**, 248–255 (2017).
- 520 59. Emmett, P. M. & Rogers, I. S. Properties of human milk and their relationship with maternal  
521 nutrition. *Early Hum. Dev.* **49**, S7–S28 (1997).
- 522 60. Bravi, F. *et al.* Impact of maternal nutrition on breast-milk composition: a systematic review. *Am. J.*  
523 *Clin. Nutr.* **104**, 646–662 (2016).
- 524 61. Robertson, R. C., Manges, A. R., Finlay, B. B. & Prendergast, A. J. The Human Microbiome and Child  
525 Growth – First 1000 Days and Beyond. *Trends Microbiol.* **27**, 131–147 (2019).
- 526 62. Das, J. K. *et al.* Preventive lipid-based nutrient supplements given with complementary foods to  
527 infants and young children 6 to 23 months of age for health, nutrition, and developmental  
528 outcomes. *Cochrane Database Syst. Rev.* **5**, CD012611 (2019).
- 529 63. Park, J. J. H. *et al.* Association of Early Interventions With Birth Outcomes and Child Linear Growth in  
530 Low-Income and Middle-Income Countries: Bayesian Network Meta-analyses of Randomized Clinical  
531 Trials. *JAMA Netw. Open* **2**, e197871–e197871 (2019).
- 532 64. Casanovas, M. del C. *et al.* Multi-sectoral interventions for healthy growth - Carmen Casanovas -  
533 2013 - Maternal & Child Nutrition - Wiley Online Library. *Matern. Child. Nutr.* **9**, 46–57 (2013).


- 534 65. Ruel, M., Alderman, H. & Maternal and Child Nutrition Study Group. Nutrition-sensitive  
535 interventions and programmes: how can they help to accelerate progress in improving maternal and  
536 child nutrition? *Lancet* **382**, 536–51 (2013).
- 537 66. Perumal, N. *et al.* Effect of correcting for gestational age at birth on population prevalence of early  
538 childhood undernutrition. *Emerg. Themes Epidemiol.* **15**, 3 (2018).
- 539  
540



541  
 542 **Figure 1 | Summaries of included *ki* cohorts. (a)** Number of observations (1000s) by age in months. **(b)**  
 543 Mean length-for-age Z-scores by age in months for each cohort. Cohorts are sorted by geographic region  
 544 and mean length-for-age Z-score. **(c)** Number of observations contributed by each cohort. **(d)** Overall  
 545 stunting prevalence in each cohort, defined as proportion of measurements with length-for-age z-score  
 546  $< -2$ .  
 547



548  
549 **Figure 2 | Length-for-age Z-scores by age and region.** (a) Kernel density distributions of length-for-age  
550 z-scores (LAZ) in Demographic and Health Surveys (DHS) in countries that overlap with *ki* cohorts  
551 stratified by geographic region. DHS estimates use the most recent survey from all countries in each  
552 region. Open circles indicate median LAZ in *ki* cohorts; closed circles indicate median LAZ in DHS cohorts.  
553 (b) Mean LAZ by age for DHS studies and *ki* longitudinal cohorts with at least quarterly measurement  
554 estimated with cubic splines. Shaded bands are approximate 95% simultaneous confidence intervals.  
555



556  
557  
558

559

560


561 **Figure 3 | Prevalence and incidence of stunting by age and region.** (a) Age-specific stunting prevalence  
562 and (b) Age-specific stunting incidence (cumulative and new cases) overall (N=21-30 studies; N=13,349-  
563 52,389 children) and stratified by region (Africa: N=4-7 studies, N=4,396-15,666 children; Latin America:  
564 N=3-5 studies, N=705-1,460 children; South Asia 12-18 studies, N=6,592-28,785 children). "0-3" includes  
565 age 2 days up to 3 months. Panels (a) and (b) include cohorts with at least quarterly measurements;  
566 vertical bars indicate 95% confidence intervals. (c) Mean length-for-age Z-score (LAZ) stratified by age of

567 incident stunting from birth to age 15 months (N=14 cohorts that measured children at least monthly  
568 between birth and age 15 months, N=7,198 children). “Never” includes children who did not become  
569 stunted by age 15 months. Shaded ribbons indicate 95% confidence intervals. Pooled results were  
570 derived from random effects models with restricted maximum likelihood estimation.


571

572

573




574  
575  
576



577  
578

579 **Figure 4| Relationship between LAZ and stunting status.** (a) Percentage of children stunted and not  
580 stunted by age (N=18 cohorts with at least monthly measurements, N=10,669 children). (b) Distribution  
581 of LAZ at subsequent measurements after stunting reversal. (c) Mean difference in LAZ following  
582 stunting reversal at each subsequent age of measurement compared to the age of reversal using  
583 random effects models fit with restricted maximum likelihood estimation. (b) and (c) include data from  
584 18 cohorts in 10 countries with at least monthly measurement (N = 10,677 children). All panels contain  
585 data up to age 15 months because in most cohorts; measurements were less frequent above 15 months.

586



587

588

589 **Figure 5 | Linear growth velocity by age and sex.** (a) Within-child difference in length in centimeters per  
 590 month stratified by age among male (green line) and female (orange line) children; 15<sup>th</sup> percentile of the  
 591 WHO Growth Velocity Standards (dotted black lines); 25<sup>th</sup> percentile (dashed black line); and the 50<sup>th</sup>  
 592 percentile (solid black line). Differences were statistically significant between sexes at ages 0-3, 3-6, 15-  
 593 18, and 18-21 months. (b) Within-child difference in length-for-age Z-score per month by age and sex.  
 594 Differences were statistically significant between sexes at ages 0-3, 9-12, 12-15, 18-21, and 21-24  
 595 months. (c) Mean length-for-age Z-score by age and sex; all differences were statistically significant. All  
 596 panels include 29 *ki* cohorts in 13 countries that measured children at least quarterly (n = 50,022  
 597 children) pooled using random effects models fit with restricted maximum likelihood estimation.  
 598 Vertical bars indicate 95% confidence intervals.

599

600

## 601 Materials and Methods

602

### 603 **Study designs and inclusion criteria**

604 We included all longitudinal observational studies and randomized trials available through the *ki* project  
605 on April 2018 that met 5 inclusion criteria: 1) conducted in low- or middle-income countries; 2) enrolled  
606 children between birth and age 24 months and measured their length and weight repeatedly over time;  
607 3) did not restrict enrollment to acutely ill children; 4) enrolled at least 200 children; 5) collected  
608 anthropometry measurements at least every 3 months (Extended Data Figure 1). Thirty-one longitudinal  
609 cohorts in 15 countries followed between 1969 and 2014 met inclusion criteria. There was no evidence  
610 of secular trends in LAZ (<https://child-growth.github.io/stunting/secular-trends.html>). We calculated  
611 cohort measurement frequency as the median days between measurements. If randomized trials found  
612 effects on growth within the intervention arms, the analyses were limited to the control arm. We  
613 included all measurements under 24 months of age, assuming months were 30.4167 days. We excluded  
614 extreme measurements of LAZ > 6 or < -6 following WHO growth standard recommendations.<sup>1</sup> In many  
615 studies, investigators measured length shortly after birth because deliveries were at home, but the  
616 majority of measurements were within the first 7 days of life ([https://child-](https://child-growth.github.io/stunting/age-meas.html)  
617 [growth.github.io/stunting/age-meas.html](https://child-growth.github.io/stunting/age-meas.html)); for this reason, we grouped measurements in the first 7 days  
618 as birth measurements. Gestational age was measured in only eight cohorts (7 cohorts measured it by  
619 recall of last menstrual period or newborn examination; 1 measured it by ultrasound); thus, we did not  
620 attempt to exclude preterm infants from the analyses.

621

### 622 **Quality assurance**

623 The *ki* data team assessed the quality of individual cohort datasets by checking the range of each  
624 variable for outliers and values that are not consistent with expectation. Z-scores were calculated using  
625 the median of replicate measurements and the 2006 WHO Child Growth Standards.<sup>1</sup> In a small number  
626 of cases a child had two anthropometry records at the same age, in which case we used the mean of the  
627 records. Analysts reviewed bivariate scatter plots to check for expected correlations (e.g., length by  
628 height, length/height/weight by age, length/height/weight by corresponding Z-score). Once the  
629 individual cohort data was mapped to a single harmonized dataset, analysts conducted an internal peer  
630 review of published articles for completeness and accuracy. Analysts contacted contributing  
631 investigators to seek clarification about potentially erroneous values in the data and revised the data as  
632 needed.

633

### 634 **Outcome definitions**

635 We used the following summary measures in the analysis:

636

637 Prevalent stunting was defined as the proportion of measurements within a specific stratum (e.g., age)  
638 below the 2006 WHO standard -2 LAZ, and analogously below -3 LAZ for severe stunting. For each age,  
639 we included children with LAZ measurements within one month before and after that age in the point  
640 prevalence estimate to account for variation in the exact age of child measurement. For example, point  
641 prevalence at 6 months included children aged 5-7 months.

642

643 Incident stunting episodes were defined as a change in LAZ from above -2 Z in the prior measurement to  
644 below -2 Z in the current measurement. Similarly, we defined severe stunting episodes using the -3 Z  
645 cutoff. Children were considered at risk of stunting at birth, so children born stunted were considered  
646 to have an incident episode of stunting at birth. Children were also assumed to be at risk of stunting at  
647 the first measurement in non-birth cohorts and trials. Children whose first measurement occurred after

648 birth were assumed to have experienced stunting onset at the age halfway between birth and the first  
649 measurement. The vast majority of children were less than 5 days of age at their first measurement life  
650 (<https://child-growth.github.io/stunting/age-meas.html>).

651  
652 Incidence proportion We calculated the incidence proportion of stunting during a defined age range  
653 (e.g. 3-6 months) as the proportion of children at risk of becoming stunted who became stunted during  
654 the age range (the onset of new episodes).

655  
656 Changes in stunting status were classified using the following categories: “Never stunted”: children with  
657 LAZ  $\geq -2$  at previous ages and the current age. “No longer stunted”: children who previously reversed  
658 their stunting status with LAZ  $\geq -2$  at the current age. “Stunting reversal”: children with LAZ  $< -2$  at the  
659 previous age and LAZ  $\geq -2$  at the current age. “Newly stunted”: children whose LAZ was previously  
660 always  $\geq -2$  and with LAZ  $< -2$  at the current age. “Stunting relapse”: children who were previously  
661 stunted with LAZ  $\geq -2$  at the previous age and LAZ  $< -2$  at the current age. “Still stunted”: children whose  
662 LAZ was  $< -2$  at the previous and current age.

663  
664 Growth velocity was calculated as the change in length in centimeters between two time points divided  
665 by the number of months between the time points. We compared the change in length in centimeters  
666 per month measures to the WHO Child Growth Standards for linear growth velocity.<sup>2</sup> We also estimated  
667 within-child rates of change in LAZ per month.

#### 668 669 **Measurement frequency**

670 Analyses of prevalence, incidence, and growth velocity (Figs 2, 3, 5) included cohorts with at least  
671 quarterly measurements in order to include as many cohorts as possible. Analyses of fluctuations in  
672 stunting status (Fig 4) were restricted to cohorts with at least monthly measurements to allow  
673 evaluation of changes in stunting status with higher resolution.

#### 674 675 **Subgroups of interest**

676 We stratified the above outcomes within the following subgroups: child age, grouped into one- or three-  
677 month intervals, (depending on the analysis); the region of the world (Asia, sub-Saharan Africa, Latin  
678 America); child sex, and the combinations of those categories.

#### 679 680 **Statistical analysis**

681 All analyses were conducted in R version 3.4.2.<sup>3</sup>

#### 682 683 Estimation of mean LAZ by age in Demographic and Health Surveys and *ki* cohorts

684  
685 We downloaded standard DHS individual recode files for each country from the DHS program  
686 website (<https://dhsprogram.com/>). We used the most recent standard DHS datasets for the individual  
687 women’s, household, and height and weight datasets from each country. We obtained variables for  
688 country code, sample weight, cluster number, primary sampling unit, and design stratification from the  
689 women’s individual survey recode files. From the height and weight dataset, we used standard recode  
690 variables corresponding to the 2006 WHO growth standards for height-for-age.

691  
692 After excluding missing observations, restricting to measurements of children 0-24 months of age,  
693 and restricting to z-scores within WHO-defined plausible values, surveys collected from 2006 to 2018 in  
694 51 countries were included (Extended Data Table 2). Surveys from Afghanistan, Bolivia, Brazil, Central

695 African Republic, Colombia, Indonesia, Nicaragua, Philippines, Paraguay, and Vietnam did not meet  
696 these inclusion criteria and were excluded from the analysis.

697

698 We classified countries into regions (South Asia, Latin America, and Africa) using the World Health  
699 Organization regional designations with the exception of the classification for Pakistan, which we  
700 included in South Asia to be consistent with prior linear growth studies using DHS.<sup>4</sup> One included cohort  
701 was from Belarus, and we chose to exclude it from region-stratified analyses as it was the only European  
702 study.

703

704 We estimated age-stratified mean from ages 0 to 24 months within each DHS survey, accounting for  
705 the complex survey design and sampling weights. We then pooled estimates of mean LAZ for each age in  
706 months across countries using a fixed effects estimator (details below). We computed two sets of  
707 pooled results: 1) DHS measuring children 0-24 months in countries that overlapped with *ki* study  
708 countries and 2) all DHS countries measuring children 0-24 months in each geographic region (as in Fig  
709 2) and (<https://child-growth.github.io/stunting/DHS.html>). We compared DHS estimates with mean LAZ  
710 by age in the *ki* study cohorts, which we estimated using penalized cubic-splines with bandwidth chosen  
711 using generalized cross-validation.<sup>5</sup> We used splines to estimate age-dependent mean LAZ in the *ki* study  
712 cohorts to smooth any age-dependent variation in the mean caused by less frequently measured  
713 cohorts.

714

#### 715 Fixed and random effects models

716

717 Several analyses pooled results across study cohorts. The primary method of pooling was using random  
718 effects models. This modeling approach assumes that studies are randomly drawn from a hypothetical  
719 population of longitudinal studies that could have been conducted on children's linear growth in the  
720 past or future. We also fit fixed effects models as a sensitivity analysis ([https://child-  
721 growth.github.io/stunting/fixed-effects.html](https://child-growth.github.io/stunting/fixed-effects.html)); inferences about estimates from fixed effects models are  
722 restricted to only the included studies.<sup>6</sup>

723

724 Random effects models assume that the true population outcomes  $\theta$  are normally distributed with  
725 mean  $\mu$  and variance  $\tau^2$  (i.e., that  $\theta \sim N(\mu, \tau^2)$ ). To estimate outcomes in this study, the random effects  
726 model is defined as follows for each study in the set of  $i = 1, \dots, k$  studies:

727

$$728 \quad y_i = \mu + u_i + e_i \quad (1)$$

729

730 where  $y_i$  is the observed outcome in study  $i$ ,  $u_i$  is the random effect for study  $i$ , and  $e_i$  is the estimated  
731 outcome for study  $i$ , and  $e_i$  is the sampling error within study  $i$ . The model assumes that  $u_i \sim N(0, \tau^2)$  and  
732  $e_i \sim N(0, v_i)$ , where  $v_i$  is the study-specific sampling variance. We fit random effects models using the  
733 restricted maximum likelihood estimator.<sup>7,8</sup> If a model failed to converge, models were fit using a  
734 maximum likelihood estimator instead. The estimate of  $\mu$  is the estimated mean outcome in the  
735 hypothetical population of studies (i.e., the estimated outcome pooling across study cohorts).

736

737 We also fit inverse variance weighted fixed effects models defined as follows:

738

$$739 \quad \bar{\theta}_w = \frac{\sum_{i=1}^k w_i \theta_i}{\sum_{i=1}^k w_i} \quad (2)$$

740

741 where  $\bar{\theta}_w$  is the weighted mean outcome in the set of  $k$  included studies, and  $w_i$  is a study-specific  
742 weight, defined as the inverse of the study-specific sampling variance  $v_i$ .  $\bar{\theta}_w$  is the estimated mean  
743 outcome in the specific studies included in this analysis.

744

745 For both types of outcomes, we pooled binary outcomes on the logit scale and then back-  
746 transformed estimates after pooling to constrain confidence intervals between 0 and 1. For cohort-  
747 stratified analyses, which did not pool across studies, we estimated 95% confidence intervals using the  
748 normal approximation (<https://child-growth.github.io/stunting/cohort.html>).

749

750 For the estimates of changes in stunting status, to ensure that percentages summed to 100%, results  
751 in Fig 4a were not pooled using random effects. Results were similar when pooling with random effects  
752 (<https://child-growth.github.io/stunting/fixed-effects.html#changes-in-stunting-status-by-age>).

753

#### 754 Estimation of prevalence and incidence

755 We estimated prevalence and incidence as defined above in 3-month age intervals within specific  
756 cohorts and pooled within region and across all studies (Fig 3). Pooled analyses used random effects  
757 models for the primary analysis and fixed effects models for sensitivity analyses as described above.

758

#### 759 Estimation of changes in stunting status

760 To assess fluctuations in stunting status over time, we conducted an analysis among cohorts with at  
761 least monthly measurements from birth through age 15 months to provide sufficient granularity to  
762 capture changes in stunting status. Because only 12 cohorts in 10 countries met these criteria, we  
763 performed only pooled analyses (i.e., we did not stratify by region or study cohort) to ensure the sample  
764 size was sufficient. We estimated the proportion of children in each stunting category defined above  
765 under “Changes in stunting status” at each month from birth to 15 months. To ensure that percentages  
766 summed to 100%, we present results that were not pooled using random effects. Analyses using random  
767 effects produced similar results ([https://child-growth.github.io/stunting/fixed-effects.html#changes-in-](https://child-growth.github.io/stunting/fixed-effects.html#changes-in-stunting-status-by-age)  
768 [stunting-status-by-age](https://child-growth.github.io/stunting/fixed-effects.html#changes-in-stunting-status-by-age)).

769

770 To examine the distribution of LAZ among children with stunting reversal, we created subgroups of  
771 children who experienced stunting reversal at ages 3, 6, 9, and 12 months and then summarized the  
772 distribution of the children’s LAZ at ages 6, 9, 12, and 15 months. Within each age interval, we estimated  
773 the mean difference in LAZ at older ages compared to the age of stunting reversal and estimated 95%  
774 confidence intervals for the mean difference. Pooled analyses used random effects models for the  
775 primary analysis and fixed effects models for sensitivity analyses as described above.

776

#### 777 Linear growth velocity

778 We estimated linear growth velocity within 3-month age intervals stratified by sex, pooling across  
779 study cohorts (Fig 5) as well as stratified by geographic region (Extended Data Fig 4) and study cohort  
780 (<https://child-growth.github.io/stunting/cohort.html>). Analyses included cohorts that measured children  
781 at least quarterly. We included measurements within a two-week window around each age in months to  
782 account for variation in the age of each length measurement. Pooled analyses used random effects  
783 models for the primary analysis and fixed effects models for sensitivity analyses as described above  
784 (<https://child-growth.github.io/stunting/fixed-effects.html>).

785

#### 786 **Sensitivity Analyses**

787 We conducted three sensitivity analyses; results are available at ([https://child-](https://child-growth.github.io/stunting)  
788 [growth.github.io/stunting](https://child-growth.github.io/stunting)). First, to assess whether inclusion of PROBIT, the single European cohort,

789 influenced our overall pooled inference, we repeated analyses excluding the PROBIT cohort. Results  
790 were very similar with and without the PROBIT cohort. Second to explore the influence of differing  
791 numbers of cohorts contributing data at different ages, we conducted a sensitivity analysis in which we  
792 subset data to cohorts that measured anthropometry monthly from birth to 24 months (n=8 cohorts in 8  
793 countries, 8,457 children. Third, we compared estimates pooled using random effects models presented  
794 in the main text with estimates pooled using fixed effects inverse variance weighted models. The  
795 random effects approach was more conservative in the presence of study heterogeneity.

796  
797 **Data and code availability:** The data that support the findings of this study are available from the Bill  
798 and Melinda Gates Foundation Knowledge Integration project upon reasonable request. Replication  
799 scripts for this analysis are available here: <https://github.com/child-growth/ki-longitudinal-growth>.

800

## 801 Methods References

- 802 1. WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-  
803 age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods  
804 and development. *Geneva World Health Organ.* 312 pages (2006).
- 805 2. WHO. *WHO Child Growth Standards: Growth Velocity Based on Weight, Length and Head*  
806 *Circumference: Methods and Development.* (2009).
- 807 3. R Core Team. *R: A language and environment for statistical computing.* <https://www.R-project.org/>  
808 (2019).
- 809 4. Victora, C. G., de Onis, M., Hallal, P. C., Blössner, M. & Shrimpton, R. Worldwide timing of growth  
810 faltering: revisiting implications for interventions. *Pediatrics* **125**, e473-480 (2010).
- 811 5. Wood, S. N., Pya, N. & Säfken, B. Smoothing Parameter and Model Selection for General Smooth  
812 Models. *J. Am. Stat. Assoc.* **111**, 1548–1563 (2016).
- 813 6. Hedges, L. V. & Vevea, J. L. Fixed- and random-effects models in meta-analysis. *Psychol. Methods* **3**,  
814 486–504 (1998).
- 815 7. Viechtbauer, W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects  
816 Model. *J. Educ. Behav. Stat.* **30**, 261–293 (2005).
- 817 8. Raudenbush, S. W. Analyzing Effect Sizes: Random-Effects Models. in *The Handbook of Research*  
818 *Synthesis and Meta-Analysis* 295–315 (Russell Sage Foundation, 2009).

## 819 Acknowledgments

820 This research was financially supported by a global development grant (OPP1165144) from the Bill &  
821 Melinda Gates Foundation to the University of California, Berkeley, CA, USA. We would also like to thank  
822 the following collaborators on the included cohorts and trials for their contributions to study planning,  
823 data collection, and analysis: Muhammad Sharif, Sajjad Kerio, Ms. Urosa, Ms. Alveen, Shahneel Hussain,  
824 Vikas Paudel (Mother and Infant Research Activities), Anthony Costello (University College London),  
825 Benjamin Torun, Lindsey M Locks, Christine M McDonald, Roland Kupka, Ronald J Bosch, Rodrick  
826 Kisenge, Said Aboud, Molin Wang, Azaduzzaman, Abu Ahmed Shamim, Rezaul Haque, Rolf Klemm,  
827 Sucheta Mehra, Maithilee Mitra, Kerry Schulze, Sunita Taneja, Brinda Nayyar, Vandana Suri, Poonam  
828 Khokhar, Brinda Nayyar, Poonam Khokhar, Jon E Rohde, Tivendra Kumar, Jose Martines, Maharaj K  
829 Bhan, and all other members of the study staffs and field teams. We would also like to thank all study  
830 participants and their families for their important contributions.

831

## 832 Author contributions

833 Conceptualization: J.B., A.M., J.M.C., K.H.B., P.C., B.F.A

834 Funding Acquisition: J.M.C., A.E.H., M.J.V., B.F.A.

835 Data curation: J.B., A.M., J.C., O.S., W.C., A.N., N.N.P., W.J., E.O.C., S.D., N.H., I.M., H.L., R.H., V.S., J.H.,  
836 T.N.

837 Formal analyses: J.B., A.M., J.C., O.S., W.C., A.N., N.N.P., W.J., E.O.C., S.D., N.H., I.M., H.L., V.S., B.F.A

838 Methodology: J.B., A.M., J.M.C., J.C., O.S., N.H., I.M., A.E.H., M.J.V., K.H.B., P.C., B.F.A.

839 Visualization: J.B., A.M., A.N., N.N.P., S.D., A.S., J.C., R.H., K.H.B., P.C., B.F.A.

840 Writing – Original Draft Preparation: J.B., A.M., B.F.A.

841 Writing – Review & Editing: J.B., A.M., J.M.C., K.H.B., P.C., B.F.A., *ki* Child Growth Consortium members

842

843

## 844 Competing interest declaration

845 Thea Norman is an employee of the Bill & Melinda Gates Foundation (BMGF). Kenneth H Brown and  
846 Parul Christian are former employees of BMGF. Jeremy Coyle, Vishak Subramoney, Ryan Hafen, and  
847 Jonas Häggström work as research contractors funded by the BMGF.

848

## 849 Additional information


850 Supplementary Information is available for this paper here: <https://child-growth.github.io/stunting/>

851

852 Correspondence and requests for materials should be addressed to Jade Benjamin-Chung


853 ([jadebc@berkeley.edu](mailto:jadebc@berkeley.edu)) and Benjamin F. Arnold ([ben.arnold@ucsf.edu](mailto:ben.arnold@ucsf.edu)).

854



856 **Extended Data Figure 1 | *ki* cohort selection.** Analyses focused on longitudinal cohorts to enable the  
857 estimation of prospective incidence rates and growth velocity. In April 2018, there were 86 longitudinal  
858 studies on GHAP. From this set, we applied five inclusion criteria to select cohorts for analysis. Our  
859 rationale for each criterion follows. (1) *Studies were conducted in lower income or middle-income*  
860 *countries.* Our target of inference for analyses was children in LMICs, which remains a key target  
861 population for preventive interventions. (2) *Studies measured length and weight between birth and age*  
862 *24 months.* We were principally interested in growth faltering during the first 1,000 days (including  
863 gestation), thought to be the key window for linear growth faltering.<sup>7</sup> (3) *Studies did not restrict*  
864 *enrollment to acutely ill children.* Our focus on descriptive analyses led us to target, to the extent  
865 possible, the general population. We thus excluded some studies that exclusively enrolled acutely ill  
866 children, such as children who presented to hospital with acute diarrhea or who were severely  
867 malnourished. (4) *Studies enrolled at least 200 children.* Age-stratified incident episodes of stunting and  
868 wasting were sufficiently rare that we wanted to ensure each cohort would have enough information to  
869 estimate rates before contributing to pooled estimates. (5) *Studies collected anthropometry*  
870 *measurements at least every 3 months.* We limited studies to those with higher temporal resolution to  
871 ensure that we adequately captured incident episodes and recovery.  
872  
873

874



875

876

877 **Extended Data Figure 2 | Stunting prevalence by geographic location of *ki* cohorts.** Locations are  
878 approximate, represented as nation-level centroids and jittered slightly for display. The size of each  
879 centroid indicates the number of observations contributing to each estimate. The color of each centroid  
880 indicates the level of stunting prevalence.


881

882


883

884


885



886  
887 **Extended Data Figure 3 | Mean, 5th and 95<sup>th</sup> percentile of length-for-age Z-score by age in *ki***  
888 longitudinal cohorts estimated with cubic splines in cohorts with at least monthly measurement (N=14  
889 cohorts that measured children at least monthly, N=7,456 children).  
890



891  
 892 **Extended Data Figure 4 | Linear growth velocity by age and sex stratified by region.** a) Within-child  
 893 difference in length in centimeters per month stratified by age, sex, and region. Dotted black line  
 894 indicates 15<sup>th</sup> percentile of the WHO Growth Velocity Standards; dashed black line indicates the 25<sup>th</sup>  
 895 percentile; solid black line indicates the 50<sup>th</sup> percentile. Colored lines indicate and vertical bars indicate  
 896 95% confidence intervals for *ki* cohorts. (b) Within-child difference in length-for-age Z-score per month  
 897 by age, sex, and region. (c) Mean length-for-age Z-score by age, sex, and region. Results shown in all  
 898 panels were derived from 29 *ki* cohorts in 13 countries that measured children at least quarterly (n =  
 899 50,022 children).  
 900



901  
 902 **Extended Data Figure 5 | Comparison of stunting prevalence at birth with and without gestational age**  
 903 **correction**

904 This figure includes the results from correcting at-birth Z-scores in the *ki* cohorts that measured  
 905 gestational age (GA) for 37,218 measurements in 8 cohorts. The number in the parentheses following  
 906 each cohort name indicates the prevalence of pre-term birth in each cohort. The corrections are using  
 907 the Intergrowth standards and are implemented using the R *growthstandards* package ([https://ki-  
 908 tools.github.io/growthstandards/](https://ki-tools.github.io/growthstandards/)). Overall, the stunting prevalence at birth decreased slightly after  
 909 correcting for gestational age, but the cohort-specific results are inconsistent. Observations with GA  
 910 outside of the Intergrowth standards range (<168 or > 300 days) were dropped for both the corrected  
 911 and uncorrected data. Prevalence increased after GA correction in some cohorts due to high rates of  
 912 late-term births based on reported GA. Gestational age was estimated based on mother’s recall of the  
 913 last menstrual period in the Jivita-3, Cebu, New Delhi, INCAP, IRC, and CMC-V-BCS-2002 cohorts, was  
 914 based on the Dubowitz method (newborn exam) in the Keneba cohort, and was based on ultrasound  
 915 measurements in the PROBIT trial.

916  
 917

918 **Extended Data Table 1 | Summary of *ki* cohorts**  
 919

Region, Study ID	Country	Study Years	Design	Children Enrolled*	Anthropometry measurement ages (months)	Total measurements*	Primary References
<b>South Asia</b>							
Biomarkers for EE	Pakistan	2013-2015	Prospective cohort	379	Birth, 1, 2, ..., 18	8484	Iqbal et al 2018 Nature Scientific Reports <sup>1</sup>
Resp. Pathogens	Pakistan	2011 - 2014	Prospective cohort	284	Birth, 1, 2, ..., 17	3177	Ali et al 2016 Journal of Medical Virology <sup>2</sup>
Growth Monitoring Study	Nepal	2012 - Ongoing	Prospective cohort	698	Birth, 1, 2, ..., 24	13465	Not yet published
MAL-ED	Nepal	2010 - 2014	Prospective cohort	240	Birth, 1, 2, ..., 24	5703	Shrestha et al 2014 Clin Infect Dis <sup>3</sup>
CMC Birth Cohort, Vellore	India	2002 - 2006	Prospective cohort	373	Birth, 0.5, 1, 1.5, ..., 24	8709	Gladstone et al. 2011 NEJM <sup>4</sup>
MAL-ED	India	2010 - 2012	Prospective cohort	251	Birth, 1, 2, ..., 24	5702	John et al 2014 Clin Infect Dis <sup>5</sup>
Vellore Crypto Study	India	2008 - 2011	Prospective cohort	410	Birth, 1, 2, ..., 24	9771	Kattula et al. 2014 BMJ Open <sup>6</sup>
CMIN	Bangladesh	1993 - 1996	Prospective Cohort	277	Birth, 3, 6, ..., 24	5363	Pathela et al 2007 Acta Paediatrica <sup>7</sup>
MAL-ED	Bangladesh	2010 - 2014	Prospective cohort	265	Birth, 1, 2, ..., 24	5604	Ahmed et al 2014 Clin Infect Dis <sup>8</sup>
PROVIDE RCT	Bangladesh	2011 - 2014	Individual RCT	700	Birth, 6, 10, 12, 14, 17, 18, 24, 39, 40, 52, 53 (weeks)	9207	Kirkpatrick et al 2015 Am J Trop Med Hyg <sup>9</sup>
Food Suppl RCT	India	1995 - 1996	Individual RCT	418	Baseline, 6, 9, 12	2232	Bhandari et al 2001 J Nutri <sup>10</sup>
Optimal Infant Feeding	India	1999 - 2001	Cluster RCT	472	Birth, 3, 6, ..., 18	2948	Bhandari et al 2004 J Nutri <sup>11</sup>
New Delhi Birth Cohort	India	1969 - 2002	Prospective cohort	7417	Birth, 3, 6, 9, 12, 18, 24	31844	Bhargava et al 2009 NEJM <sup>12</sup>
NIH Birth Cohort	Bangladesh	2008 - 2009	Prospective Cohort	629	Birth, 3, 6, ..., 12	6215	Korpe et al. 2016 PLOS NTD <sup>13</sup>

JiVita-4 Trial	Bangladesh	2012 - 2014	Cluster RCT	1434	6, 9, 12, 14, 18	9344	Christian et al 2015 IJE <sup>14</sup>
JiVita-3 Trial	Bangladesh	2008 - 2012	Cluster RCT	13475	Birth, 1, 3, 6, 12, 24	53453	West et al JAMA 2014 <sup>15</sup>
NIH Cryptosporidium Study	Bangladesh	2014 - 2017	Prospective cohort	758	Birth, 3, 6, ..., 24	6914	Steiner et al 2018 Clin Infect Dis <sup>16</sup>
The Cebu Longitudinal Health and Nutrition Survey	Philippines	1983 - 2005	Prospective cohort	3058	Birth, 2, 4, ..., 24	32518	Adair 2007 Am J Hum Biol <sup>17</sup>
<b>Africa</b>							
MAL-ED	Tanzania	2009 - 2014	Prospective cohort	262	Birth, 1, 2, ..., 24	5713	Mduma et al 2014 Clin Infect Dis <sup>18</sup>
Tanzania Child 2	Tanzania	2007 - 2011	Individual RCT	2396	1, 2, ..., 20	29565	Locks et al Am J Clin Nutr 2016 <sup>19</sup>
MAL-ED	South Africa	2009 - 2014	Prospective cohort	314	Birth, 1, 2, ..., 24	6163	Bessong et al 2014 Clin Infect Dis <sup>20</sup>
MRC Keneba	Gambia	1987 - 1997	Cohort	2915	Birth, 1, 2, ..., 24	40275	Schoenbuchner et al. 2019, AJCN <sup>21</sup>
ZVITAMBO Trial	Zimbabwe	1997 - 2001	Individual RCT	14074	Birth, 6 wks, 3, 6, 9, 12	71928	Malaba et al 2005 Am J Clin Nutr <sup>22</sup>
Lungwena Child Nutrition RCT	Malawi	2011 - 2014	Individual RCT	840	Birth, 1-6 wk, 6, 12, 18	4336	Mangani et al. 2015, Mat Child Nutr <sup>23</sup>
iLiNS-Zinc Study	Burkina Faso	2010 - 2012	Cluster RCT	797	9, 12, 15, 18	1471	Hess et al 2015 Plos One <sup>24</sup>
<b>Latin America</b>							
MAL-ED	Peru	2009 - 2014	Prospective cohort	303	Birth, 1, 2, ..., 24	6142	Yori et al 2014 Clin Infect Dis <sup>25</sup>
CONTENT	Peru	2007 - 2011	Prospective cohort	215	Birth, 1, 2, ..., 24	8339	Jaganath et al 2014 Helicobacter <sup>26</sup>
Bovine Serum RCT	Guatemala	1997 - 1998	Individual RCT	315	Baseline, 1, 2, ..., 8	2545	Begin et al. 2008, EJCNC <sup>27</sup>
MAL-ED	Brazil	2010 - 2014	Prospective cohort	233	Birth, 1, 2, ..., 24	4858	Lima et al 2014 Clin Infect Dis <sup>28</sup>
INCAP Nutrition Supplementation Trial Longitudinal Study	Guatemala	1969 - 1977	Cluster RCT	664	Birth, 3, 6, ..., 24	3708	Habicht et al 1995 J Nutr <sup>29</sup>

<b>Europe</b>							
PROBIT Study	Belarus	1996 - 1997	Cluster RCT	8127	1, 2, 3, 6, 9, 12	58649	Kramer et al 2001 JAMA <sup>30</sup>
*Children enrolled is for children with measurements under 2 years of age. Total measurements are number of measurements of anthropometry on children under 2 years of age.							

921

922

923 **Extended Data Table 2** | Countries and survey years included in the analysis of Demographic and Health  
 924 Survey data  
 925

<b>Africa</b>	
Burkina Faso	2010
Gambia	2013
Malawi	2015-2016
Tanzania	2015-2016
South Africa	2016
Zimbabwe	2015
<b>South Asia</b>	
Bangladesh	2014
India	2015-2016
Nepal	2016
Pakistan	2017-2018
<b>Latin America</b>	
Guatemala	2014-2015
Peru	2012

926  
 927  
 928  
 929  
 930

**Extended Data References**

- 931 1. Iqbal, N. T. *et al.* Promising Biomarkers of Environmental Enteric Dysfunction: A Prospective  
 932 Cohort study in Pakistani Children. *Sci. Rep.* **8**, 2966 (2018).
- 933 2. Ali, A. *et al.* Respiratory viruses associated with severe pneumonia in children under 2 years  
 934 old in a rural community in Pakistan. *J. Med. Virol.* **88**, 1882–1890 (2016).
- 935 3. Shrestha, P. S. *et al.* Bhaktapur, Nepal: The MAL-ED Birth Cohort Study in Nepal. *Clin.*  
 936 *Infect. Dis.* **59**, S300–S303 (2014).
- 937 4. Gladstone, B. P. *et al.* Protective Effect of Natural Rotavirus Infection in an Indian Birth  
 938 Cohort. *N. Engl. J. Med.* **365**, 337–346 (2011).
- 939 5. John, S. M. *et al.* Establishment of the MAL-ED Birth Cohort Study Site in Vellore, Southern  
 940 India. *Clin. Infect. Dis.* **59**, S295–S299 (2014).
- 941 6. Kattula, D. *et al.* The first 1000 days of life: prenatal and postnatal risk factors for morbidity  
 942 and growth in a birth cohort in southern India. *BMJ Open* **4**, e005404 (2014).
- 943 7. Pathela, P. *et al.* Diarrheal illness in a cohort of children 0-2 years of age in rural  
 944 Bangladesh: I. Incidence and risk factors: Risk factors for diarrhea in Bangladeshi children.  
 945 *Acta Paediatr.* **95**, 430–437 (2007).
- 946 8. Ahmed, T. *et al.* The MAL-ED Cohort Study in Mirpur, Bangladesh. *Clin. Infect. Dis.* **59**,  
 947 S280–S286 (2014).
- 948 9. Kirkpatrick, B. D. *et al.* The “Performance of Rotavirus and Oral Polio Vaccines in  
 949 Developing Countries” (PROVIDE) Study: Description of Methods of an Interventional Study  
 950 Designed to Explore Complex Biologic Problems. *Am. J. Trop. Med. Hyg.* **92**, 744–751  
 951 (2015).
- 952 10. Bhandari, N. *et al.* Food Supplementation with Encouragement to Feed It to Infants from 4  
 953 to 12 Months of Age Has a Small Impact on Weight Gain. *J. Nutr.* **131**, 1946–1951 (2001).

- 954 11. Bhandari, N. *et al.* An Educational Intervention to Promote Appropriate Complementary  
955 Feeding Practices and Physical Growth in Infants and Young Children in Rural Haryana,  
956 India. *J. Nutr.* **134**, 2342–2348 (2004).
- 957 12. Bhargava, S. K. *et al.* Relation of Serial Changes in Childhood Body-Mass Index to Impaired  
958 Glucose Tolerance in Young Adulthood. *N. Engl. J. Med.* **350**, 865 (2004).
- 959 13. Korpe, P. S. *et al.* Natural History of Cryptosporidiosis in a Longitudinal Study of Slum-  
960 Dwelling Bangladeshi Children: Association with Severe Malnutrition. *PLoS Negl. Trop. Dis.*  
961 **10**, (2016).
- 962 14. Christian, P. *et al.* Effect of fortified complementary food supplementation on child growth in  
963 rural Bangladesh: a cluster-randomized trial. *Int. J. Epidemiol.* **44**, 1862–1876 (2015).
- 964 15. West, K. P. *et al.* Effect of Maternal Multiple Micronutrient vs Iron–Folic Acid  
965 Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh: The  
966 JiVitA-3 Randomized Trial. *JAMA* **312**, 2649–2658 (2014).
- 967 16. Steiner, K. L. *et al.* Species of Cryptosporidia Causing Subclinical Infection Associated With  
968 Growth Faltering in Rural and Urban Bangladesh: A Birth Cohort Study. *Clin. Infect. Dis. Off.*  
969 *Publ. Infect. Dis. Soc. Am.* **67**, 1347–1355 (2018).
- 970 17. Adair, L. S. Size at birth and growth trajectories to young adulthood. *Am. J. Hum. Biol. Off.*  
971 *J. Hum. Biol. Counc.* **19**, 327–337 (2007).
- 972 18. Mduma, E. R. *et al.* The Etiology, Risk Factors, and Interactions of Enteric Infections and  
973 Malnutrition and the Consequences for Child Health and Development Study (MAL-ED):  
974 Description of the Tanzanian Site. *Clin. Infect. Dis.* **59**, S325–S330 (2014).
- 975 19. Locks, L. M. *et al.* Effect of zinc and multivitamin supplementation on the growth of  
976 Tanzanian children aged 6–84 wk: a randomized, placebo-controlled, double-blind trial.  
977 *Am. J. Clin. Nutr.* **103**, 910–918 (2016).
- 978 20. Bessong, P. O., Nyathi, E., Mahopo, T. C. & Netshandama, V. Development of the Dzimauli  
979 Community in Vhembe District, Limpopo Province of South Africa, for the MAL-ED Cohort  
980 Study. *Clin. Infect. Dis.* **59**, S317–S324 (2014).
- 981 21. Schoenbuchner, S. M. *et al.* The relationship between wasting and stunting: a retrospective  
982 cohort analysis of longitudinal data in Gambian children from 1976 to 2016. *Am. J. Clin.*  
983 *Nutr.* doi:10.1093/ajcn/nqy326.
- 984 22. Malaba, L. C. *et al.* Effect of postpartum maternal or neonatal vitamin A supplementation on  
985 infant mortality among infants born to HIV-negative mothers in Zimbabwe. *Am. J. Clin. Nutr.*  
986 **81**, 454–460 (2005).
- 987 23. Mangani, C. *et al.* Effect of complementary feeding with lipid-based nutrient supplements  
988 and corn–soy blend on the incidence of stunting and linear growth among 6- to 18-month-  
989 old infants and children in rural Malawi. *Matern. Child. Nutr.* **11**, 132–143 (2015).
- 990 24. Hess, S. Y. *et al.* Small-Quantity Lipid-Based Nutrient Supplements, Regardless of Their  
991 Zinc Content, Increase Growth and Reduce the Prevalence of Stunting and Wasting in  
992 Young Burkinabe Children: A Cluster-Randomized Trial. *PLOS ONE* **10**, e0122242 (2015).
- 993 25. Yori, P. P. *et al.* Santa Clara de Nanay: The MAL-ED Cohort in Peru. *Clin. Infect. Dis.* **59**,  
994 S310–S316 (2014).
- 995 26. Jaganath, D. *et al.* First Detected *Helicobacter pylori* Infection in Infancy Modifies the  
996 Association Between Diarrheal Disease and Childhood Growth in Peru. *Helicobacter* **19**,  
997 272–279 (2014).
- 998 27. Bégin, F., Santizo, M.-C., Peerson, J. M., Torún, B. & Brown, K. H. Effects of bovine serum  
999 concentrate, with or without supplemental micronutrients, on the growth, morbidity, and  
1000 micronutrient status of young children in a low-income, peri-urban Guatemalan community.  
1001 *Eur. J. Clin. Nutr.* **62**, 39–50 (2008).
- 1002 28. Lima, A. A. M. *et al.* Geography, Population, Demography, Socioeconomic, Anthropometry,  
1003 and Environmental Status in the MAL-ED Cohort and Case-Control Study Sites in Fortaleza,  
1004 Ceará, Brazil. *Clin. Infect. Dis.* **59**, S287–S294 (2014).

- 1005 29. Habicht, J.-P., Martorell, R. & Rivera, J. A. Nutritional Impact of Supplementation in the  
1006 INCAP Longitudinal Study: Analytic Strategies and Inferences. *J. Nutr.* **125**, 1042S-1050S  
1007 (1995).  
1008 30. Kramer, M. S. *et al.* Promotion of Breastfeeding Intervention Trial (PROBIT): A Randomized  
1009 Trial in the Republic of Belarus. *JAMA* **285**, 413–420 (2001).  
1010